Cancer-Focused Arrivent Biopharma Eyes $150M IPO
Lung cancer-focused Arrivent Biopharma Inc. set a price range for its planned initial public offering Monday, saying it plans to offer 8.3 million shares at a price range of $17 to...To view the full article, register now.
Already a subscriber? Click here to view full article